277 related articles for article (PubMed ID: 24815083)
1. Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging.
Massa S; Xavier C; De Vos J; Caveliers V; Lahoutte T; Muyldermans S; Devoogdt N
Bioconjug Chem; 2014 May; 25(5):979-88. PubMed ID: 24815083
[TBL] [Abstract][Full Text] [Related]
2. Sortase A-mediated site-specific labeling of camelid single-domain antibody-fragments: a versatile strategy for multiple molecular imaging modalities.
Massa S; Vikani N; Betti C; Ballet S; Vanderhaegen S; Steyaert J; Descamps B; Vanhove C; Bunschoten A; van Leeuwen FW; Hernot S; Caveliers V; Lahoutte T; Muyldermans S; Xavier C; Devoogdt N
Contrast Media Mol Imaging; 2016 Sep; 11(5):328-339. PubMed ID: 27147480
[TBL] [Abstract][Full Text] [Related]
3. PET Imaging of Macrophage Mannose Receptor-Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody Fragments.
Blykers A; Schoonooghe S; Xavier C; D'hoe K; Laoui D; D'Huyvetter M; Vaneycken I; Cleeren F; Bormans G; Heemskerk J; Raes G; De Baetselier P; Lahoutte T; Devoogdt N; Van Ginderachter JA; Caveliers V
J Nucl Med; 2015 Aug; 56(8):1265-71. PubMed ID: 26069306
[TBL] [Abstract][Full Text] [Related]
4. Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target.
De Vos J; Devoogdt N; Lahoutte T; Muyldermans S
Expert Opin Biol Ther; 2013 Aug; 13(8):1149-60. PubMed ID: 23675652
[TBL] [Abstract][Full Text] [Related]
5. Specific targeting of atherosclerotic plaques in ApoE(-/-) mice using a new Camelid sdAb binding the vulnerable plaque marker LOX-1.
De Vos J; Mathijs I; Xavier C; Massa S; Wernery U; Bouwens L; Lahoutte T; Muyldermans S; Devoogdt N
Mol Imaging Biol; 2014 Oct; 16(5):690-8. PubMed ID: 24687730
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
[TBL] [Abstract][Full Text] [Related]
7. ⁹⁹mTc-labeled single-domain antibody EG2 in targeting epidermal growth factor receptor: an in-vitro and mouse model in-vivo study.
Li C; Wen B; Wang L; Feng H; Xia X; Ding Z; Gao B; Zhang Y; Lan X
Nucl Med Commun; 2015 May; 36(5):452-60. PubMed ID: 25591074
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of radiolabeled dimeric sdAbs constructs targeting human CD20.
Krasniqi A; Bialkowska M; Xavier C; Van der Jeught K; Muyldermans S; Devoogdt N; D'Huyvetter M
N Biotechnol; 2018 Oct; 45():69-79. PubMed ID: 29574274
[TBL] [Abstract][Full Text] [Related]
9. Effect of Dye and Conjugation Chemistry on the Biodistribution Profile of Near-Infrared-Labeled Nanobodies as Tracers for Image-Guided Surgery.
Debie P; Van Quathem J; Hansen I; Bala G; Massa S; Devoogdt N; Xavier C; Hernot S
Mol Pharm; 2017 Apr; 14(4):1145-1153. PubMed ID: 28245129
[TBL] [Abstract][Full Text] [Related]
10. Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[
Zhou Z; McDougald D; Devoogdt N; Zalutsky MR; Vaidyanathan G
Mol Pharm; 2019 Jan; 16(1):214-226. PubMed ID: 30427188
[TBL] [Abstract][Full Text] [Related]
11. Emerging site-specific bioconjugation strategies for radioimmunotracer development.
Massa S; Xavier C; Muyldermans S; Devoogdt N
Expert Opin Drug Deliv; 2016 Aug; 13(8):1149-63. PubMed ID: 27116898
[TBL] [Abstract][Full Text] [Related]
12. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
[TBL] [Abstract][Full Text] [Related]
13. Contributions of the complementarity determining regions to the thermal stability of a single-domain antibody.
Zabetakis D; Anderson GP; Bayya N; Goldman ER
PLoS One; 2013; 8(10):e77678. PubMed ID: 24143255
[TBL] [Abstract][Full Text] [Related]
14. Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent.
Feng Y; Zhou Z; McDougald D; Meshaw RL; Vaidyanathan G; Zalutsky MR
Nucl Med Biol; 2021 Jan; 92():171-183. PubMed ID: 32448731
[TBL] [Abstract][Full Text] [Related]
15. Site-Specific and Residualizing Linker for
Zhou Z; Meshaw R; Zalutsky MR; Vaidyanathan G
J Nucl Med; 2021 Nov; 62(11):1624-1630. PubMed ID: 33637584
[TBL] [Abstract][Full Text] [Related]
16. The GEM-handle as convenient labeling strategy for bimodal single-domain antibody-based tracers carrying
Declerck NB; Huygen C; Mateusiak L; Stroet MCM; Hernot S
Front Immunol; 2023; 14():1285923. PubMed ID: 38035094
[TBL] [Abstract][Full Text] [Related]
17. Novel therapy based on camelid nanobodies.
Unciti-Broceta JD; Del Castillo T; Soriano M; Magez S; Garcia-Salcedo JA
Ther Deliv; 2013 Oct; 4(10):1321-36. PubMed ID: 24116915
[TBL] [Abstract][Full Text] [Related]
18. Nanobodies: natural single-domain antibodies.
Muyldermans S
Annu Rev Biochem; 2013; 82():775-97. PubMed ID: 23495938
[TBL] [Abstract][Full Text] [Related]
19. Antigen recognition by single-domain antibodies: structural latitudes and constraints.
Henry KA; MacKenzie CR
MAbs; 2018; 10(6):815-826. PubMed ID: 29916758
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic nanoparticle targeting of the EGF-receptor in complex biological conditions using single-domain antibodies.
Zarschler K; Prapainop K; Mahon E; Rocks L; Bramini M; Kelly PM; Stephan H; Dawson KA
Nanoscale; 2014 Jun; 6(11):6046-56. PubMed ID: 24777583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
